quizartinib
Phase 3 Trial Validates FLT3-ITD MRD as Target for FLT3-ITD-Positive AML
New findings demonstrate the prognostic utility of FLT3-ITD-specific MRD measurements in the clinical management of ...
JANUARY 22, 2024
Vanflyta Approved for Newly Diagnosed Acute Myeloid Leukemia
The FDA approved quizartinib (Vanflyta, Daiichi Sankyo) with standard cytarabine and anthracycline induction and ...
JULY 24, 2023
Quizartinib Poised to Change Treatment Paradigm for AML
Adding quizartinib (Daiichi Sankyo) to standard chemotherapy and consolidation significantly improves overall ...
JULY 13, 2022
Load more